Overview: CK-MB Mass TestIntroduction: The CK-MB Mass Test measures CK-MB to diagnose heart attack, causing chest pain or shortness of breath. Aligned with 2023 AHA guidelines, it uses an immunoassay for high sensitivity, aiding in cardiovascular screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected myocardial infarction.
Other Names: CK-MB Assay, Cardiac Enzyme Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: CK-MB testing began in the 1970s with heart attack research. Immunoassays emerged in the 1980s, and by the 2000s, high-sensitivity assays improved diagnostic accuracy.
Purpose: Diagnoses heart attack, guides treatment, and monitors CK-MB levels in patients with chest pain or shortness of breath.
Test Parameters: 1. CK-MB Mass
Pretest Condition: No fasting required. Collect serum or plasma at any time. Report symptoms like chest pain or shortness of breath, and list medications like aspirin.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document chest pain, shortness of breath, or history of heart disease. Include current medications, especially aspirin or statins.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cardiac treatment.
Procedural Considerations: Uses an immunoassay to measure CK-MB levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Hemolysis or improper storage can degrade samples. Recent exercise may elevate CK-MB levels.
Clinical Significance: Elevated CK-MB levels confirm heart attack, prompting urgent treatment. Normal levels suggest alternative diagnoses.
Specialist Consultation: Consult a cardiologist for result interpretation. An emergency physician referral is advised for acute cases.
Additional Supporting Tests: Troponin test, ECG, or cardiac catheterization to confirm heart attack or assess heart damage.
Test Limitations: False positives may occur with skeletal muscle injury. Results require clinical correlation with cardiac markers.
References: AHA Cardiac Guidelines, 2023; Circulation, Thygesen K, 2022.
